Get started

Healthcare

SPHealth 2 Week Comparisons (Oct 7-20 2020)SPHealth - Growth Analysis & Comparison - Cindicator Poll Submission (October 7th - 20th 2020) I've been looking through my Cindicator questions, making forecasts and watching markets as new polls pop up. Here's a comparison chart for 5 major S&P health companies and my rankings forecast. (Descending order from most growth to least) United Health Group Inc (UNH) Abbott Labs (ABT) Johnson & Johnson (JNJ) Pfizer Inc. (PFE) Merck & Co. (MRK) This forecast will be explicitly graded by total growth % comparisons of opening prices on October 7th to closing prices on October 20th across the 5 aforementioned companies. As of right now before 10-9-20 daily market open, the percentage growth is as follows: UNH +1.9% PFE +1.87% JNJ +1.56% ABT +1.1% MRK +0.54% When looking at a specific metric within the already completed duration since I submitted my forecast, overall recent growth is: UNH +2.82% PFE +2.66% JNJ +2.24% MRK +2.22% ABT +1.62% 10-9-20 Forecast Adjustments: Now that I have seen the last 2 days play out, I'm starting to notice a couple things about my forecast and actual live value. I'm confident that United Health will still outperform, but this outlook could change if any major market sell off occurs before the 20th. Pfizer looks like it could be a strong runner up, and I may have flubbed my original forecast by ranking it 4th in growth. Johnson & Johnson is performing approximately as expected. Merck and Abbott Labs could be tricky to pinpoint exactly without some further research and analysis but, I'm guessing that Abbott may come in 4th place if everything settles after any quick rallies that should happen. If a light pump in Merck occurs over the 19th-20th, then there could be a small chance it outperforms Abbott for 4th but it feels like an unlikely scenario. After these deliberations, I've decided my forecast doesn't need much adjusting other than to swap the placement of Pfizer and Abbott. My updated forecast is as follows: United Health Group Inc (UNH) Pfizer Inc. (PFE) Johnson & Johnson (JNJ) Abbott Labs (ABT) Merck & Co. (MRK) One thing to note is that I believe TradingView is not calculating its percentage scale correctly, its placing the 0% Y axis at the close value of the first candle used to calculate growth. So this graph is really just more for me to check my own work by hand, as the percentages on the left will not accurately portray what is actually being graded by Cindicator. I'll check back in after the 20th to see how this turned out! Thanks for tuning in :) Disclaimer, I am not responsible for any losses incurred while attempting to use my data, I hope this can prove to be some sort of learning tool for some and give insight as to how I personally come up with my own numbers. Take into full consideration this could be a completely bad forecast. Cheers
NYSE:UNH
by Hambooger
$LMAT can rise in the next daysContextual immersion trading strategy idea. LeMaitre Vascular, Inc. designs, markets, sells, services, and supports medical devices and implants for the treatment of peripheral vascular disease worldwide. The demand for shares of the company looks higher than the supply. This and other conditions can cause a rise in the share price in the next days. So I opened a long position from $33,45; stop-loss — $32,46. Information about take-profits will be later. Do not view this idea as a recommendation for trading or investing. It is published only to introduce my own vision. Always do your own analysis before making deals. When you use any materials, do not rely on blind trust. You should remember that isolated deals do not give systematic profit, so trade/invest using a developed strategy. If you like my content, you can subscribe to the news and receive my fresh ideas. Thanks for being with me!
NASDAQ:LMATLong
by KozakHlib
$AVDL can fall in the next daysContextual immersion trading strategy idea. Avadel Pharmaceuticals operates as a specialty pharmaceutical company in the United States, France, and Ireland. The demand for shares of the company looks lower than the supply. This and other conditions can cause a fall in the share price in the next days. So I opened a short position from $5,23; stop-loss — $5,89. Information about take-profits will be later. Do not view this idea as a recommendation for trading or investing. It is published only to introduce my own vision. Always do your own analysis before making deals. When you use any materials, do not rely on blind trust. You should remember that isolated deals do not give systematic profit, so trade/invest using a developed strategy. If you like my content, you can subscribe to the news and receive my fresh ideas. Thanks for being with me!
NASDAQ:AVDLShort
by KozakHlib
$CODX can rise in the next daysContextual immersion trading strategy idea. Co-Diagnostics, Inc., a molecular diagnostics company, intends to manufacture and sell reagents used for diagnostic tests that function via the detection and/or analysis of nucleic acid molecules. The share price rose after the company announced that it had entered into an agreement with Arches Research, a subsidiary of Polarity TE (NASDAQ:PTE), to expand Arches' use of Co-Diagnostics' Logix Smart COVID-19 test. The demand for shares of the company still looks higher than the supply. These and other conditions can cause a rise in the share price in the next days. So I opened a long position again from $11,62; stop-loss — $10,80. Information about take-profits will be later. Do not view this idea as a recommendation for trading or investing. It is published only to introduce my own vision. Always do your own analysis before making deals. When you use any materials, do not rely on blind trust. You should remember that isolated deals do not give systematic profit, so trade/invest using a developed strategy. If you like my content, you can subscribe to the news and receive my fresh ideas. Thanks for being with me!
NASDAQ:CODXLong
by KozakHlib
$MASI can fall in the next daysContextual immersion trading strategy idea. Masimo Corporation, a medical technology company, develops, manufactures, and markets noninvasive monitoring technologies and hospital automation solutions worldwide. The demand for shares of the company looks lower than the supply. This and other conditions can cause a fall in the share price in the next days. So I opened a short position from $218,41; stop-loss — $221,56. Information about take-profits will be later. Do not view this idea as a recommendation for trading or investing. It is published only to introduce my own vision. Always do your own analysis before making deals. When you use any materials, do not rely on blind trust. You should remember that isolated deals do not give systematic profit, so trade/invest using a developed strategy. If you like my content, you can subscribe to the news and receive my fresh ideas. Thanks for being with me!
NASDAQ:MASIShort
by KozakHlib
2
Possible Head & Shoulders for APHA?A H&S pattern is clearly noticeable on the RSI & KST. On the KST the right shoulder is lower than the left, but on the price the right shoulder is higher than the left, not sure if that's considered a bearish divergence but if there's further downside action it would seem accurate. On the KST each shoulder & the head display a bearish cross where I have placed the red finger, this happens when the red line crosses over the green in a downward angle.
A
by ScotianBot
1
Buying opportunity in CVS after Walgreens earnings bombCVS is pulling back in sympathy with Walgreens after WBA earnings were a dud. However, the adverse impact on Walgreens sales was "almost entirely from the company's non-U.S. businesses," according to the company's report. CVS operates almost exclusively in the United States, with 9,750 US locations and just 150 internationally. This suggests that CVS should be relatively insulated from the fall-off in international demand that Walgreens saw. CVS is in almost every way a better company than Walgreens. It has better analyst ratings, better financial health, and a much better valuation in terms of PEG ratio. Its dividend yield and dividend growth are lower, but its growth plan has been more aggressive, with the rollout of HealthHub stores and telehealth services continuing on schedule amidst the pandemic. Walgreens has lagged behind CVS in its plans to add healthcare clinics to its retail stores. CVS's relationship with UPS may prove an additional tailwind amidst the pandemic. Walgreens partners with UPS's smaller competitor, FedEx.
NYSE:CVSLong
by ChristopherCarrollSmith
DVAX- Is Approaching A Critical Level: 50%/120% potential profitDVAX - Is Approaching A Critical Level: DVAX- Is Approaching A Critical Level: 50%/120% potential profit Here’s A Way to Play It. see chart info: DVAX Dynavax Technologies Corporation Healthcare | Biotechnology | USA NEWS for Dynavax Technologies Corporation : as of August 13, 2020 www.fool.com finance.yahoo.com DISCLAIMER: Futures, stocks and options trading involves substantial risk of loss and is not suitable for every investor. The valuation of futures, stocks and options may fluctuate, and, as a result, may lose more than their original investment. All trading strategies , CHART are used at your own risk. ...
NASDAQ:DVAXLong
by Voxeurh514
TOPGLOV 1/8/2020Riding on the healthcare demand theme, topglov's share price has risen significantly in the past few months. While many are doubting the sustainability of the valuation and the continuous rally, investors/operator interest in glove counters seemed to be unfazed, with new highs charted almost every week. Chart and indicator wise, it seems like topglove is consolidating and inching upwards with an oversold RSI in the 1 hour chart. Based on the indicator, it seems like its a good entry now. i am still optimistic about this counter and believe it may chart higher highs in the future because 1) Health care product demand continue to surge 2) Most 2nd and 3rd tier healthcare counters across the world just had a rally 3) Results are expected to be spectacular due to its sheer production capacity and product mix compared to others 4) Share Split proposal Hartalega QR will be out this week. If history will repeat itself, we will likely to see a sharp correction in the glove sector after the publication of Harta's quarterly report, just like the last one. This is only my observation, lets revisit next week and see if it happens. EP: RM24-RM25 TP: RM30-RM31 CL: RM22-RM23
MYX:TOPGLOVLong
by jasontkj
Recommend adding Cardinal Health to your watch list - $64 TargetThis is more of investment logic than trading logic. I was keeping an eye on Cardinal to see if this Inverted H&D would play out, and it did not. Will be watching to see where it finds support - I am expecting it will be off the 20dma. If we see a nice morning star, or bullish hammer I will be looking to build a long from that point. I am keeping an eye on the weekly TF, not the daily as the reason I want to be in CAH is for the cheap value and 3.55% Dividend. Market Cap 15.96B Income -4158M Sales 153.59B Book/sh 4.12 Forward P/E 9.90 (Very inexpensive) P/FCF 12.46 (Bullish) Debt/Eq 6.04 EPS this Y +308% Sales Q/Q +11.2% EPS Q/Q +20.3% Earnings Aug 6th Gross Margin +4.5% ROE -176.4% (Very bearish) Profit MArgin -2.7% Short Float 1.75% Long term Target will be $64
NYSE:CAH
by ZenMode
2